文献速递类风湿关节炎

背景治疗对类风湿关节炎随机对照试验中安慰剂反应的影响

Impact of pre-existing background therapy on placebo responses in randomised controlled clinical trials of rheumatoid arthritis.
PubMed 文献 · Ann Rheum Dis · 2022-06-20

该研究事后分析了两项允许纳入正在使用或未使用甲氨蝶呤(MTX)患者的随机对照试验(GO-AFTER和SIRROUND-T)中的安慰剂组患者。合并398例安慰剂患者,285例继续使用MTX,113例无背景改善病情抗风湿药(DMARDs)。第16周时,安慰剂+继续MTX组ACR20应答率高于安慰剂单用组,ACR50亦较高。结论认为继续不足量MTX背景治疗的患者安慰剂反应更高,提示试验期间背景治疗摄入更持续,建议入组前有效调整背景治疗。

要点

  • 继续MTX的安慰剂组第16周ACR20应答率为25.3%,高于无背景DMARDs组的12.4%(名义p=0.005)。
  • 继续MTX的安慰剂组第16周ACR50应答率为8.4%,高于无背景DMARDs组的0.9%(名义p=0.003)。
  • 继续MTX的安慰剂组第16周CDAI-LDA应答率为8.8%,高于无背景DMARDs组的1.8%(名义p=0.013)。

核心结论

  • 继续不足量MTX背景治疗的患者对安慰剂的临床反应更高,提示试验期间背景治疗摄入可能更持续,建议入组前有效调整背景治疗。

研究设计与样本

  • 对GO-AFTER和SIRROUND-T两项随机对照试验中安慰剂治疗患者进行事后分析,两项试验均允许纳入正在使用或未使用MTX的患者。
  • 合并两项试验的安慰剂患者共398例,其中285例继续使用MTX,113例无任何背景DMARDs。

主要发现

  • 第16周,安慰剂+继续MTX组ACR20应答为72/285(25.3%),安慰剂单用组为14/113(12.4%),名义p=0.005。
  • 第16周,安慰剂+继续MTX组ACR50应答为25/285(8.4%),安慰剂单用组为1/113(0.9%),名义p=0.003。
  • 第16周,安慰剂+继续MTX组ACR70应答为8/285(2.8%),安慰剂单用组为0/113(0%),名义p=0.112。
  • 第16周,安慰剂+继续MTX组CDAI-LDA应答为25/285(8.8%),安慰剂单用组为2/113(1.8%),名义p=0.013。
  • 两组基线特征相似。

关键数值与推荐

  • ACR20应答率:安慰剂+继续MTX组72/285(25.3%)vs 安慰剂单用组14/113(12.4%),名义p=0.005。
  • ACR50应答率:安慰剂+继续MTX组25/285(8.4%)vs 安慰剂单用组1/113(0.9%),名义p=0.003。
  • ACR70应答率:安慰剂+继续MTX组8/285(2.8%)vs 安慰剂单用组0/113(0%),名义p=0.112。
  • CDAI-LDA(CDAI≤10)应答率:安慰剂+继续MTX组25/285(8.8%)vs 安慰剂单用组2/113(1.8%),名义p=0.013。

临床怎么用

  • 作者建议入组临床试验前应有效调整背景治疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Various hypotheses exist for the explanation of placebo response rates in randomised controlled trials (RCTs) of patients with rheumatoid arthritis with IR to methotrexate (MTX). We hypothesised that placebo responses may be related to more consequent intake of MTX during the tightly monitored trial period. METHODS: We conducted a post hoc analysis of placebo-treated patients included in two RCTs that had allowed inclusion of patients with and without ongoing MTX: the GO-AFTER and the SIRROUND-T trials. We pooled placebo patients of both trials and compared American College of Rheumatology (ACR) 20%/50%/70% response rates and Clinical Disease Activity Index (CDAI) low disease activity (LDA; ie, CDAI ≤10) responses between those receiving placebo on top of continued MTX and those receiving placebo without any background disease modifying antirheumatic drugs (DMARDs). RESULTS: Of 398 placebo patients, 285 continued MTX and 113 had no background DMARDs. Baseline characteristics were similar. At week 16, ACR20 response was achieved by 72/285 (25.3%) of placebo+continued MTX and 14/113 (12.4%) of placebo only patients (nominal p=0.005); for ACR50 these numbers were 25/285 (8.4%) versus 1/113 (0.9%; nominal p=0.003) and for ACR70 they were 8/285 (2.8%) versus 0/113 (0%; nominal p=0.112). Also, more patients with placebo+continued MTX achieved CDAI-LDA at week 16 (25/285; 8.8%) compared with placebo only (2/113; 1.8%; nominal p=0.013). CONCLUSION: Clinical responses to placebo are higher in patients who continue an insufficient MTX background therapy. This suggests an inadvertently more consequent intake of background therapy during the trial. Background therapy should therefore be effectively aligned before enrollment into a clinical trial.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Kerschbaumer A, Rivai ZI, Smolen JS, et al. Impact of pre-existing background therapy on placebo responses in randomised controlled clinical trials of rheumatoid arthritis. Ann Rheum Dis. 2022. PMID: 35725294. doi:10.1136/annrheumdis-2021-221807

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。